Cylinder Health Partners with Stonebrook to Tackle Rising Digestive Disease Costs
Event summary
- Cylinder Health and Stonebrook Risk Solutions announced a strategic partnership on February 23, 2026, to expand digestive disease management capabilities.
- The partnership aims to address the growing medical and pharmacy spend associated with digestive conditions like IBD, IBS, GERD, and celiac disease.
- Cylinder Health’s virtual-first, multidisciplinary program will be offered nationwide through Stonebrook’s ecosystem.
- The program focuses on earlier intervention, stabilization of high-acuity cases, and improved predictability of medical and pharmacy spend.
The big picture
The partnership addresses a critical gap in managing digestive diseases, which are often overlooked despite being significant drivers of medical and pharmacy spend. By integrating Cylinder Health’s specialized program into Stonebrook’s ecosystem, the collaboration aims to reduce avoidable hospitalizations and high-cost pharmacy utilization, aligning with broader industry trends toward proactive, multidisciplinary care.
What we're watching
- Cost Containment
- How the partnership will affect the management of high-cost biologic therapies and catastrophic claims for TPAs and regional health plans.
- Program Adoption
- The pace at which employers and health plans integrate Cylinder Health’s program into their existing benefit and claims infrastructures.
- Outcome Metrics
- Whether the validated clinical, economic, and patient experience metrics will deliver measurable ROI for large employers.
Related topics